These alterations may pose significant cardiometabolic risks to these women, particularly hypertension, resistance to insulin action, type 2 diabetes mellitus, dyslipidemia, and cardiovascular diseases [65,66,67,68,69,70]. This evidence concerns the gene INS and type 2 diabetes mellitus.